Association of QT interval-prolonging drugs with clinical trial eligibility in patients with advanced cancer

INTRODUCTION: Drug-induced prolongation of the heart rate-corrected QT interval (QTc) is associated with increased risk for the potentially fatal arrhythmia torsades de pointes. Due to arrhythmia risk, clinical trials with cancer therapeutics often exclude patients based on thresholds for QTc prolon...

Descripción completa

Detalles Bibliográficos
Autores principales: Rowe, Elizabeth J., Shugg, Tyler, Ly, Reynold C., Philips, Santosh, Rosenman, Marc B., Callaghan, John T., Radovich, Milan, Overholser, Brian R., Schneider, Bryan P., Tisdale, James E., Skaar, Todd C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Cardiovascular Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9798408/
https://www.ncbi.nlm.nih.gov/pubmed/36588548
http://dx.doi.org/10.3389/fcvm.2022.894623

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9798408/
https://www.ncbi.nlm.nih.gov/pubmed/36588548
http://dx.doi.org/10.3389/fcvm.2022.894623

Ejemplares similares